We believe that having invested and dedicated leadership begins with a management team that encourages innovation and creative thought processes amongst employees. Our management team encompasses a diverse background of experience and credentials that support and enhance our company’s goals.
The board of directors understands our company and takes the time to conduct thorough reviews and ask challenging questions in a continual effort to increase long-term shareholder value.
Gerald (Gerry) D. Sakowski
Chief Executive Officer
Gerry Sakowski joined CMP Pharma in July 2013. Sakowski brings 32 years of experience working within contract services and generic drug development and commercialization. Previous positions include staff scientist at Oneida Research Services, Whitesboro, NY, and Analytical Business Manager at Applied Analytical Industries (AAI), Wilmington, NC. From 1997-2013, Sakowski held positions with Metrics, Inc. as Director of Marketing and Sales, Vice President of Business Development, Sr. Vice President and COO, and most recently, Executive Vice President of Commercial Operations. He earned his Bachelor of Science degrees in biology and chemistry from Evangel University in Springfield, Missouri.
Chief Financial Officer
Brad joined CMP in 2022 and has over 15 years of financial and accounting experience in the pharmaceutical and medical device industry with a focus on strategic planning, forecasting, financial modeling, accounting operations, and team leadership. Brad’s previous positions include VP of Finance at SunTech Medical, Director of FP at Chiesi Pharmaceuticals, and financial auditor at EY. Brad has a BSBA in business/computer information systems from Appalachian State University, a Master of Accounting from the University of North Carolina at Chapel Hill, and is a licensed CPA in the state of North Carolina.
Vice President, Operations
Anthony Pipho joined CMP Pharma in August 2014. Pipho brings 18 years of experience in the pharmaceutical industry. Past experiences include various positions of increasing responsibility with Metrics, Inc. and CMP Pharma focusing on analytical, formulation, and process development of pharmaceutical products including solid, semi-solid, oral suspensions/solutions, and sterile injectable dosage forms. He is responsible for oversight of Operations at CMP Pharma including product development, commercial manufacturing, regulatory, purchasing and logistics. He has a Bachelor of Science degree in biochemistry from East Carolina University.
Director of Sales
Allan Slizewski joined CMP Pharma in September 2013. Slizewski brings 35 years of experience working in pharmaceutical sales, marketing and business development experience. Previous positions include VP of Sales and Marketing at Paddock Laboratories and Product Manager at Roxane Laboratories. He has a Bachelor’s Degree in Business Administration from Arizona State University.
Jonathan D. Kuhn
Vice President of Commercial
Jonathan Kuhn joined CMP Pharma in June 2017. Jon brings over 22 years of pharmaceutical industry experience including over 15 years of branded pharmaceutical marketing and several product launches. Previous positions include Senior Director, U.S. Parkinson’s Disease & Neuropathic Pain Marketing and Director U.S. & Global, Multiple Sclerosis & Spasticity Brand Marketing at Acorda Therapeutics. He has a Bachelor’s of Science in management from the University of Bloomsburg and has an MBA in marketing from DeSales University.
Vice President of Business Development
Kris Ford joined CMP Pharma in 2022. Kris brings over 25 years of experience in the biotech and pharmaceutical industries. His prior experience includes leading commercial, marketing and sales, and strategic BD&L teams; growing a multibillion-dollar pharma portfolio via efficient pipeline development, innovative life-cycle management, and flexible M&A and business development strategies; and advising leadership on product launches/commercial execution, BD value transformation strategies, and M&A/licensing. He holds BS MS degrees from NC State University and an MBA in Finance from UNC Wilmington.
John Dilda joined CMP Pharma in 1986. Dilda brings 30 years of pharmaceutical manufacturing experience and earned an Associate degree in Applied Science.
Director of Quality Assurance
Melanie Little Joined CMP Pharma in February 2017. Little brings 20 years of related pharmaceutical quality experience to the team. Previous positions include QA Specialist, QA Supervisor, Principal Quality Associate, Regulatory Compliance Audit Support for DSM Pharmaceuticals, Metrics, Inc. and Mayne Pharma, Inc. Melanie has an Associates of Applied Science in Biotechnology from Pitt Community College.
Mr. Callahan currently serves as an independent advisor to global biopharmaceutical companies. Previously, he spent over two decades in leadership positions within the industry, most recently serving as SVP, Commercial Operations at Actavis (now Allergan). Prior to this, Mr. Callahan held positions of increasing responsibility in general management and commercial leadership at Actavis, Watson Pharmaceuticals, and Schein Pharmaceutical. Mr. Callahan serves on the Board of Directors for Synergy Pharmaceuticals (NASDAQ: SGYP), and he is a Senior Advisor to McKinsey & Company. Mr. Callahan holds a Bachelor of Science degree in Applied Economics and Business Management from Cornell University.
Steve Cagle is the Chairman of the Board of CMP Pharma. Previously, Mr. Cagle served as CEO of Moberg Pharma North America (formerly Alterna LLC) and prior to that was a principal management team member of Sparta Systems, where he served in various sales, marketing, and operational roles. He is currently the CEO of Clearwater, a healthcare focused cybersecurity and risk management company focused on serving the healthcare industry. Mr. Cagle received a Bachelor of Science from Rutgers and a Master of Business Administration from NYU Stern School of Business.
Garikai is a principal at Altaris. Prior to joining Altaris, Garikai was an engagement manager in the private equity and healthcare practices of McKinsey & Company where he completed numerous transaction and corporate strategy engagements. Garikai received an M.S. in Financial Economics from Oxford University and a B.S. in Economics from The University of Cape Town.